DNMT1 and neoplasm: Inhibitors of epigenetic modulators such as DNA methyltransferase 1 (DNMT1), histone deacetylases (HDACs) and bromodomain and extra-terminal (BET) inhibitors have shown capabilities to function as differentiation therapies for CSCs in various tumor types (Toh et al., 2017).